Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
Research and Development Programs
Neurocrine Biosciences’ research group continues to advance novel small molecule compounds into clinical development. Neurocrine Biosciences scientists are focusing on developing small molecule modulators of G-protein coupled receptors (GPCRs), solute carrier proteins (SLCs) and ion channels.
GPCRs are the largest known gene superfamily of the human genome. Greater than 30 percent of all marketed prescription drugs act on GPCRs, which makes this class of proteins historically the most successful therapeutic target family. However, only a small fraction of the GPCR gene superfamily has been exploited. The SLC family of metabolite transporters is a supergroup of membrane proteins comprising more than 400 members arranged across more than 50 families. SLCs are the gatekeepers for metabolite pathways, controlling the movement of metabolites in and out of cells and organelles. As regulators of the location of hundreds of metabolites, which serve as important communication channels for cells, SLCs play a crucial role in health and disease. Ion channels appear to be represented by approximately 400 genes in the human genome and are currently the targets for approximately 7 percent of the current marketed drugs. Neurocrine Biosciences believes that next-generation therapies derived from targeting these classes of proteins will be discovered through the understanding of the complex relationships of drug/receptor interactions and their subsequent impact on efficacy, downstream signaling networks and regulation.
Neurocrine Biosciences’ research platform has met this requirement by integrating drug discovery research efforts with a suite of assays and assay systems and automated analytical techniques. This process provides an unbiased profile of pharmacological protein/ligand interactions coupled with in vivo efficacy using discrete animal models, allowing for rapid discovery of initial leads and advancement into preclinical and clinical development. Importantly, this design cycle is not limited to GPCRs, solute carrier proteins or ion channel targets, but can be utilized for other recently identified proteins that play a role in human disease where current treatments or therapies are either inadequate or nonexistent.
Neurocrine Biosciences Corporate Information
The Company’s common stock is traded on the Nasdaq Global Select Market System under the symbol “NBIX”
Telephone: (858) 617-7600
12780 El Camino Real
San Diego, CA 92130
Telephone: (858) 617-7600
Fax: (858) 617-7602